<DOC>
	<DOCNO>NCT01707732</DOCNO>
	<brief_summary>Venous thromboembolism ( VTE ) , deep vein thrombosis ( DVT ) pulmonary embolism ( PE ) common medical condition encounter hospitalization medical environment . The use thromboprophylaxis Low Molecular Weight Heparin ( LMWH ) fondaparinux reduce 50 % relative risk thromboembolic complications.However , obesity define body mass index ( BMI ) great 30 kg/m2 , major risk factor venous thrombotic event , data obese patient limited . In fact , less 20 % patient include three major study preventive medicine BMI ≥ 30 kg/m2 study specific obese population come series bariatric surgery patient orthopedic surgery . The main result series show regard obese population decrease anti-Xa activity administration standard dose enoxaparin ( 40 mg / ) . However , specific recommendation population publish date therefore , dosages currently use regardless patient 's weight . In context , use obese patient hospitalize medical environment strong dosage enoxaparin ( 60 mg / ) compare standard dose 40 mg / day , could get rate anti-Xa activity level consistent treatment require , thus reduce risk thromboembolic complication patient</brief_summary>
	<brief_title>Adjusted Value Thromboprophylaxis Hospitalized Obese Patients : A Comparative Study Two Regimens Enoxaparin</brief_title>
	<detailed_description />
	<criteria>1 . Patient age ≥ 18 an . 2 . Signed inform consent 3 . Obesity define BMI value ≥ 30 kg/m2 . 4 . Hospitalized : acute medical affection : congestive heart failure ( stage III IV NYHA ) , severe respiratory disease , Infectious disease acute rheumatologic disorder inflammatory bowel disease one additional risk factor , include active cancer , previous VTE , age &gt; 75 yo , estrogen therapy , chronic heart failure chronic respiratory disease recent myocardial infarction ( &lt; 6 week ) , recent stroke hemiparesis ( &lt; 15 day ) , previous VTE , myeloproliferative syndrome associate one additional risk previously cite . 5 . Affiliation welfare system . 1 . Subjects unwilling unable comply study procedures 2 . History hypersensitivity enoxaparin heparin induce thrombocytopenia 3 . Previous history heparin induce thrombopenia 4. acquire inherited bleeding diathesis coagulopathy , 5 . Platelet count &lt; 50.000 G/L , 6 . History clinically significant bleed 7 . Severe renal insufficiency CrCl &lt; 30 ml/min ( Cockcroft method ) , 8 . Pregnancy breastfeed 9 . Women without contraceptive method 10 . Severe peripheral arterial disease ( Ankle blood pressure &lt; 50mm Hg ) 11 . Concomitant anticoagulant therapy 12 . Severe psychiatric disease 13 . History disease psychological sensory anomaly susceptible prevent subject understand indeed condition require participation protocol prevent give enlightened consent 14 . Person deprive liberty administrative judicial decision , person legal guardianship person 15 . Patient participate trial participate another medicinal trial within 1 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Obesity</keyword>
	<keyword>thromboprophylaxis</keyword>
	<keyword>Enoxaparin</keyword>
</DOC>